Overview and Scope
Cardiac biomarkers are chemicals released by heart into the blood when it is injured or under stress. It used for the detection and measurement of various cardiac vascular diseases.
Sizing and Forecast
The cardiac biomarkers market size has grown rapidly in recent years. It will grow from $17.22 billion in 2023 to $19.48 billion in 2024 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to increased healthcare expenditure, fda approvals and regulatory support, aging population, awareness programs, high sensitivity troponin tests, increasing cardiovascular diseases.
The cardiac biomarkers market size is expected to see rapid growth in the next few years. It will grow to $31.88 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to rising burden of chronic diseases, growing emphasis on early disease detection, expansion of geriatric population, emerging markets development, focus on biomarker panels. Major trends in the forecast period include patient-centric healthcare models, ai and machine learning applications, digital health integration, technological innovations in biomarker discovery, multi-marker panels, liquid biopsy in cardiovascular medicine.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report
Segmentation & Regional Insights
The cardiac biomarkers market covered in this report is segmented –
1) By Biomarkers Type: Creatine Kinase (CK-Mb), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarker Types
2) By Location Of Testing: Point Of Care Testing, Laboratory Testing
3) By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome (ACS), Atherosclerosis, Other Applications
4) By End User: Hospitals, Specialty Clinics
North America was the largest region in the cardiac biomarkers market in 2023. The regions covered in the cardiac biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10234&type=smp
Major Driver Impacting Market Growth
The rising prevalence of cardiovascular disorders is expected to propel the growth of the cardiac biomarker market going forward. Cardiovascular disorders are diseases that affect the heart and blood vessels and include conditions such as coronary artery disease, heart failure, and stroke. Cardiac biomarkers are released into the bloodstream in response to certain cardiovascular disorders, such as myocardial infarction (heart attack), heart failure, and arrhythmias, that can be measured using laboratory tests, and their levels can provide important diagnostic and prognostic information. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based public agency, coronary artery disease (CAD) was responsible for killing 375,476 people in 2021, and about 1 in 20 adults age 20 and older had CAD. In addition, about 2 in 10 deaths from CAD happen to adults less than 65 years old. Therefore, the rising prevalence of cardiovascular disorders is driving the growth of the cardiac biomarker market.
Key Industry Players
Major companies operating in the cardiac biomarkers market report are bioMerieux Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Siemens AG, Thermo Fisher Scientific Inc., Creative Diagnostics, Randox Laboratories Ltd., Becton Dickinson and Company, Tosoh Corporation, Life Diagnostics, PerkinElmer Inc., Quidel Corporation, ACS Biomarker BV, LSI Medience Corp., BioDot, Alere Inc., Biosensors International Group, Biosynex SA, CardioGenics Holdings Inc., Danaher Corporation, Cortez Diagnostics Inc., DIALAB GmbH, Eurolyser Diagnostica GmbH, Grifols SA, Hologic Inc., InfraRedx Inc., Labcorp Corp., Lepu Medical Technology, Myriad Genetics, Nanosphere Inc., Biora Therapeutics Inc., Quest Diagnostics
The cardiac biomarkers market report table of contents includes:
.
.
.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Overview and Scope Diagnostic specialty antibodies refer to a class of antibodies that are specifically…
Overview and Scope Diabetic retinopathy is an eye condition that can lead to blindness and…
Overview and Scope Ocular inflammation treatment refers to medical approaches aimed at reducing swelling and…
Overview and Scope Polymerase chain reaction (PCR) is a laboratory technique used to amplify specific…
Overview and Scope Quantum security refers to the process of using quantum mechanical principles to…
Overview and Scope A smart bandage is an advanced medical dressing or wound care device…